FDA rejects Eagle Pharmaceuticals' Ryanodex By: MarketMinute.com Stock News July 26, 2017 at 17:30 PM EDT The Food and Drug Administration rejected Eagle Pharmaceuticals Inc.'s (Nasdaq: EGRX) heat stroke treatment Ryanodex. The stock price collapsed $16.67 to close at $53.37. Related Stocks: Eagle Pharmaceuticals
